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Abstract
Methionine aminopeptidases (MetAPs) represent a unique class of protease that is capable of the hydrolytic
removal of an N-terminal methionine residue from nascent polypeptide chains. MetAPs are physiologically
important enzymes; hence, there is considerable interest in developing inhibitors that can be used as
antiangiogenic and antimicrobial agents. A detailed kinetic and spectroscopic study has been performed to
probe the binding of a triazole-based inhibitor and a bestatin-based inhibitor to both Mn(II)- and Co(II)-loaded
type-I (Escherichia coli) and type-II (Pyrococcus furiosus) MetAPs. Both inhibitors were found to be moderate
competitive inhibitors. The triazole-type inhibitor was found to interact with both active-site metal ions, while
the bestatin-type inhibitor was capable of switching its mode of binding depending on the metal in the active
site and the type of MetAP enzyme.
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Introduction
Methionine aminopeptidases (MetAPs) represent a unique class of metalloprotease that is responsible for
removing N-terminal methionine residues from polypeptide chains [1, 2]. On the basis of fumagillin affinity
chromatography and mass spectrometry, MetAPs were identified as the molecular targets of ovalicin, fumagillin,
and TNP-470 [3]. The activity of this sesquiterpiene epoxide containing molecule has been evaluated for the
treatment of a variety of cancers such as Kaposi’s sarcoma, cervical cancer, brain cancer, and renal cell
carcinoma [4]. Furthermore, in vivo studies showed that one of the observed effects of the inhibition of MetAPs
by antiangiogenesis agents is the failure to expose glycine residues at the N termini of certain signaling proteins
involved in cell cycle regulation, preventing myristolyation [5]. Selective inhibition of tumor cells by targeting a
common molecule required for signal transduction of numerous growth stimulators provides an effective
approach to treat cancer [6, 7, 8, 9, 10]. MetAPs represent just such a target and, therefore, understanding the
catalytic mechanism of MetAPs is critically important for the future development of drugs that prevent tumor
vasculature formation, growth, and proliferation [11, 12, 13, 14]. In addition, sesquiterpiene epoxide containing
molecules have been shown to inhibit the in vitro growth of the malaria parasites Plasmodium falciparum and
Leishmania donavani; therefore, drug design efforts that target MetAPs may have additional applications in the
treatment of malaria and leishmaniasis [15].
MetAPs are organized into two classes (types I and II) on the basis of the absence or presence of an extra 62
amino acid sequence (of unknown function) inserted near the catalytic domain. The type-I MetAPs from
Escherichia coli (EcMetAP-I), Staphylococcus aureus, Thermotoga maritime, and Homo sapiens and the type-II
MetAPs from Homo sapiens (HsMetAP-II) and Pyrococcus furiosus (PfMetAP-II) have been crystallographically
characterized [16, 17, 18, 19, 20, 21]. All six display a novel “pita-bread” fold with an internal pseudo twofold
symmetry that structurally relates the first and second halves of the polypeptide chain to each other. Both
domains contribute conserved residues to the metallo-active site. In all six structures, a bis(μ-carboxylato)(μaquo/hydroxo)dicobalt core is observed with an additional carboxylate residue at each metal site and a single
histidine bound to Co1. An X-ray crystal structure of EcMetAP-I was recently reported with partial occupancy
(40%) of a single Mn(II) ion bound in the active site [22]. This structure was obtained by adding the transitionstate analog inhibitor l-norleucine phosphonate, to impede divalent metal binding to the second site, and by
limiting the amount of metal ion present during crystal growth. This structure provides the first structural
verification that MetAPs can form mononuclear active sites and the single divalent metal ion resides on the
H171 side of the active site as previously predicted by 1H NMR and extended X-ray absorption fine structure
spectroscopy [23, 24].
A current challenge facing the rational design of highly potent inhibitors of MetAPs is that some candidate
compounds fail to have similar efficacy between in vitro and in vivo experiments [25]. Such differences between

in vivo and in vitro effectiveness have been partially ascribed to the lack of certainty about the identity of the in
vivo metal ion for MetAPs and its stoichiometry [25, 26]. The dissimilarity in metal identity and its occupancy
number within the active site may have subtle effects on the catalytic mechanism of MetAPs, which manifests
itself in significant differences in the efficacy of potential inhibitors. It has been established that MetAPs can be
activated by Co(II), Fe(II), and Mn(II), but that Zn(II) will not activate either type-I or type-II enzymes [23, 26, 27,
28]. However, a single study on the type-I MetAP from Saccharomyces cerevisiae suggested that Zn(II) ions, in
the presence of 5 mM glutathione and 2 mM EDTA under aerobic conditions, provided an active MetAP enzyme,
while the Co(II)-containing enzyme was largely inactivated under similar conditions and no activity could be
observed in the presence of Fe(II) [29]. Even more recently, the physiologically relevant metal ion for HsMetAP-II
was shown to be Mn(II) using Co(II)-specific synthetic inhibitors to probe intracellular HsMetAP-II (Fig. 1) [25]. To
understand the mechanism of inhibitor binding to MetAP and to determine why a triazole-containing inhibitor,
3-((2-naphthylmethyl)sulfanyl)-4H-1,2,4-triazole (A-310840), strongly inhibits Co(II)-loaded HsMetAP-II but not
Mn(II)-loaded HsMetAP-II, while a bestatin-like inhibitor, ((2RS,3R)-3-amino-2-hydroxy-5-ethylthio)pentanoyl((S)-(−)-(1-naphthyl)ethyl)amide (A-311263), inhibits each metal-substituted HsMetAP-II enzyme equally well, we
have investigated the binding affinities and structural aspects of each of these inhibitor interactions with
EcMetAP-I and PfMetAP-II.

Fig. 1. Molecular structures of the triazole-like (A310840) and the bestatin-like (A311263) methionine
aminopeptidase (MetAP) inhibitors

Materials and methods
Purification of MetAP enzymes

All chemicals used in this study were purchased commercially and were of the highest quality available.
Recombinant EcMetAP-I was expressed and purified as previously described [23, 27, 28]. Purified EcMetAP-I
exhibited a single band on sodium dodecyl sulfate polyacrylamide gel electrophoresis. Protein concentrations
were obtained spectrophotometrically at 280 nm using an extinction coefficient ε 280 nm of 16,445 M−1 cm−1. ApoEcMetAP-I was washed free of methionine using Chelex-100-treated methionine-free buffer [25 mM N-(2hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES), pH 7.5, 150 mM KCl] and concentrated by
microfiltration using a Centricon-10 (Amicon, Beverly, MA, USA) prior to all kinetic assays. Individual aliquots of
apo-EcMetAP-I were routinely stored at −80 °C or in liquid nitrogen until needed.
PfMetAP-II was purified as previously reported and exhibited a single band on sodium dodecyl sulfate
polyacrylamide gel electrophoresis [28]. Protein concentrations were estimated from the absorbance at 280 nm
using an extinction coefficient ε280 nm of 21,650 M−1 cm−1. Metal-free PfMetAP-II was prepared by concentrating

purified PfMetAP-II to a volume of approximately 5 mL, after which EDTA was added to a final concentration of
10 mM. The resulting protein solution was dialyzed against 25 mM HEPES buffer (2 L, pH 7.5) containing 10 mM
EDTA and 150 mM KCl at 4 °C for 2 days with two buffer changes per day. The protein solution was then dialyzed
against Chelex-100-treated 25 mM HEPES buffer (2 L, pH 7.5) containing 150 mM KCl for 3 days against two
buffer changes per day. The resulting PfMetAP-II was inactive and found to contain no detectable metal ions via
inductively coupled plasma atomic emission spectrometry. This enzyme, deemed “apo-PfMetAP-II,” was stored
at −80 °C until needed.

Synthesis of the triazole MetAP inhibitor A-310840

The inhibitor A-310840 was synthesized as previously described [25]. Briefly, to a suspension of 3-mercapto1,2,4-triazole (0.18 g, 1.8 mmol) and cesium carbonate (0.72 g, 2.2 mmol) in 5 mL of N,N-dimethylformamide
was added 2-(bromomethyl)naphthalene (0.38 g, 1.7 mmol). The mixture was heated at 40 °C for 16 h. The
volume was reduced by rotary evaporation, and the remaining mixture was shaken with water and methylene
chloride and then filtered. The layers of the filtrate were separated, and the organic phase was dried over
magnesium sulfate. Filtration and solvent removal gave a white solid (0.143 g). Mass spectrometry (desorption
chemical ionization/NH3) m/z 242 (M + H)+, 259 (M + NH4)+; 1H NMR (300 MHz, dimethyl-d 6 sulfoxide, δ) 14.08
(s, 1H), 8.57 (bds, 1H), 7.88 (m, 4H), 7.49 (m, 3H), 4.51 (s, 2H); Anal. Calcd for C10H2ON4S: C, 64.70; H, 4.59; N,
17.41. Found: C, 64.93; H, 4.58; N, 17.25.

Synthesis of the bestatin MetAP inhibitor A-311263

The inhibitor A-311263 was synthesized as previously described from d-methionine (Aldrich Chemical Co.) [25].
Mass spectrometry (electrospray ionization + quadrupole 1 MS) m/z 347 (M + H)+, 693 (2 M + H)+; 1H NMR
(300 MHz, dimethyl-d 6 sulfoxide, δ) 8.75–7.47 (m, 7H), 6.55 (br, 1H), 4.82–4.75 (m, 1H), 4.15 (d, 1H), 3.60–3.33
(br m, 3H), 2.68–2.34 (m, 3.6H), 2.18 (q, 0.4H), 1.87–1.68 (m, 2H), 1.58–1.53 (m, 3H), 1.13 (t, 0.6H), 0.98 (t,
0.4H). Anal. Calcd for C19H27N2O2S·HCl: C, 59.59; H, 7.11; N, 7.32. Found: C, 59.54; H, 7.13; N, 7.16.

Enzymatic assay of MetAPs

All enzymatic assays were performed under strict anaerobic conditions in an inert atmosphere glove box (Coy)
with a dry bath incubator to maintain the temperature. Catalytic activities were determined with an error of
±5%. Enzyme activities for both EcMetAP-I and PfMetAP-II were determined in 25 mM HEPES buffer, pH 7.5,
containing 150 mM KCl with the tetrapeptide substrate MGMM. The amount of product formation was
determined by high-performance liquid chromatography (HPLC; Shimadzu LC-10A class-VP5). A typical assay
involved the addition of 4 μL of metal-loaded MetAP to a 16 μL substrate–buffer mixture at 30 °C for 1 min. The
reaction was quenched by the addition of 20 μL of 1% trifluoroacetic acid solution. Elution of the product was
monitored at 215 nm following separation on a C8 HPLC column (Phenomenex, Luna; 5 μm, 4.6 cm × 25 cm), as
previously described [23, 27, 28]. Enzyme activities are expressed as units per milligram, where one unit is
defined as the amount of enzyme that releases 1 μmol of product in 1 min at 30 °C. Inhibition studies were
performed by the addition of either A-310840 or A-311263 at a concentration of 0.1–2,000 μM to the assay
using a substrate concentration of 8 mM.

Isothermal titration calorimetry

Isothermal titration calorimetry (ITC) measurements were carried out with a MicroCal OMEGA ultrasensitive
titration calorimeter. The titrants (A-310840 and A-311263) and apo-MetAP solutions were prepared in Chelex100-treated HEPES buffer at pH 7.5. Stock buffer solutions were thoroughly degassed before each titration. The
enzyme solution (50–80 μM) loaded with 2 equiv of metal ions [Co(II) or Mn(II)] was placed in the calorimeter
cell and stirred at 200 rpm to ensure rapid mixing. Typically, 4–10 μL of titrant was delivered over 7.6 s with a 6min interval between injections to allow for complete equilibration. Each titration was continued until 4.5–6
equiv of inhibitor had been added to ensure that no additional complexes were formed in excess titrant. A

background titration, consisting of the identical titrant solution but only the buffer solution in the sample cell,
was subtracted from each experimental titration to account for heat of dilution. The data were analyzed with a
one- or two-site binding model by the Windows-based Origin software package supplied by MicroCal [30].

Spectroscopic measurements

Electronic absorption spectra were recorded using a Shimadzu UV-3101PC spectrophotometer. All apo-MetAP
samples used in spectroscopic measurements were made rigorously anaerobic prior to incubation with Co(II)
(CoCl2 99.999% or better purity; Strem Chemicals, Newburyport, MA, USA) for approximately 30 min at 25 °C. All
Co(II)-containing samples were handled throughout in an anaerobic glove box (Ar/5% H2, 1 ppm or less O2; Coy
Laboratories) until frozen. Electronic absorption spectra were normalized for the protein concentration and the
absorption due to uncomplexed Co(II) (ε 512 nm = 6.0 M−1 cm−1) [23]. Low-temperature EPR spectroscopy was
performed using either a Bruker ESP-300E or a Bruker EleXsys E600 spectrometer, each equipped with an ER
4116 DM dual-mode X-band cavity operating at 9.63 GHz (B 0⊥B 1) or 9.37 GHz (B 0∥B 1) and an Oxford
Instruments ESR-900 helium-flow cryostat. All spectra were recorded using 100-kHz magnetic field modulation.
Other EPR running parameters are specified in the figure legends for individual samples. EPR simulations were
carried out using matrix diagonalization (XSophe, Bruker Biospin), assuming a spin Hamiltonian H = βg
HS + SDS + SAI, with S = 3/2 and D ≫ β gHS (=hν). Enzyme concentrations for EPR were 1 mM.

Results

Determination of IC50 values

Data on inhibition of MetAP activity by A-311263 and A-310840 (IC50 values) towards the Co(II)- and Mn(II)loaded PfMetAP-II and EcMetAP-I enzymes are provided in Table 1. A-310840, a triazole-containing inhibitor,
binds potently to PfMetAP-II in the presence of Co(II) (IC50 of 15 μM) but is approximately 67-fold less potent for
Mn(II)-loaded PfMetAP-II (IC50 of 1,000 μM). A similar trend is observed for EcMetAP-I, except that A-310840
binds to the Co(II)-loaded enzyme well (IC50 of 44 μM) but is approximately 23-fold less potent for Mn(II)-loaded
EcMetAP-I (IC50 of 1,000 μM). In comparison, the bestatin-type inhibitor, A-311263, has little or no preference
for the type of divalent metal ion that occupies the active site. A-311263 also inhibits PfMetAP-II and EcMetAP-I
loaded with either Co(II) or Mn(II) similarly, with IC50 values between 20 and 34 μM.
Table 1. IC50, inhibition constants (K i), dissociation constants (K d), stoichiometry (n), and thermodynamics
parameters for 3-((2-naphthylmethyl)sulfanyl)-4H-1,2,4-triazole (A-310840) and ((2RS,3R)-3-amino-2-hydroxy-5ethylthio)pentanoyl-((S)-(−)-(1-naphthyl)ethyl)amide (A-311263) binding to Co(II)- and Mn(II)-loaded type-II
methionine aminopeptidase (MetAP) from Pyrococcus furiosus (PfMetAP-II) and type-I MetAP from Escherichia
coli (EcMetAP-I)

Wild-type enzymes
A-310840 binding to wildtype enzymes
[CoCo(PfMetAP-II)]
[MnMn(PfMetAP-II)]
[CoCo(EcMetAP-I)]
[MnMn(EcMetAP-I)]
A-311263 binding to wildtype enzymes
[CoCo(PfMetAP-II)]
[MnMn(PfMetAP-II)]

n

IC50
(μM)

1
1
1
1

15
1,000
44
1,000

1 20
1 27

Ki
(μM)

K d (μM)

∆H
(kJ/mol)

3
440
8
750

2.0 ± 0.1
666 ± 10
10 ± 0.1
714 ± 10

−5.5 ± 2
−0.3 ± 0.1
−8.36 ± 0.3
−24.6 ± 3

2
20

0.45 ± 0.11 −14.9 ± 2
26 ± 5
−62.7 ± 5

T∆S
(J/mol)

∆G
(kJ/mol)

27 × 103
17 × 103
20 × 103
−7 × 103

−32.5
−18.1
−28.5
−17.9

21 × 103
−36 × 103

−36.2
−26.1

[CoCo(EcMetAP-I)]
[MnMn(EcMetAP-I)]

1 32
1 34

3
20

2.4 ± 0.1
50 ± 5

1.57 ± 0.3
−19 ± 4

33 × 103
6 × 103

−32
−24.5

Kinetic determination of K i values

Previous work indicated that A-310840 and A-311263 are strong inhibitors of HsMetAP-II on the basis of IC50
values [25]. We have carefully examined the hydrolysis of the tetrapeptide substrate MGMM by both PfMetAP-II
and EcMetAP-I in the presence of various concentrations of A-310840 and A-311263. K i values for A-310840 and
A-311263 binding to PfMetAP-II and EcMetAP-I were obtained by fitting the kinetic data to the Michaelis–
Menten equation for competitive inhibition (Table 1). A-310840 is a much more potent competitive inhibitor
towards Co(II)-loaded PfMetAP-II (K i = 3 μM) and EcMetAP-I (K i = 8 μM) compared with the Mn(II)-loaded
PfMetAP-II (K i = 440 μM) and EcMetAP-I (K i = 750 μM) enzymes. On the other hand, A-311263 inhibits Co(II)loaded PfMetAP-II (K i = 2 μM) and EcMetAP-I (K i = 3 μM) by a magnitude similar to that of Mn(II)-loaded
PfMetAP-II (K i = 20 μM) and EcMetAP-I (K i = 20 μM).

Isothermal titration calorimetry

The use of ITC to measure the binding of exogenous ligands to biomolecules relies on the fact that such an
interaction is accompanied by a heat effect. The heat absorbed (endothermic) or released (exothermic) upon
inhibitor–enzyme interaction is used to obtain the dissociation constant, K d, and the enthalpy of binding, ΔH.
ITC measurements for the binding of A-310840 and A-311263 to Co(II)- and Mn(II)-loaded EcMetAP-I and
PfMetAP-II were carried out with a MicroCal OMEGA ultrasensitive titration calorimeter at 25.0 ± 0.2 °C. K d
values were obtained by fitting these data, after subtraction of the background heat of dilution, via an
interactive process using the Origin software package. This software package uses a nonlinear least-squares
algorithm, which allows the concentrations of the titrant and the sample to be fit to the heat flow per injection,
to an equilibrium binding equation for either one site or two noninteracting sites. The K a value, the enzyme–
metal stoichiometry (n), and the change in enthalpy (ΔH) were allowed to vary during the fitting process. The
relationship between K a and the dissociation constant is defined as K d = 1/K a. The best fits obtained for the
binding of A-310840 to Co(II)-loaded PfMetAP-II and EcMetAP-I provided an overall n value of 1 and K d values of
2.0 and 10 μM, respectively, which indicate approximately 333-fold and approximately 71-fold stronger binding
than is observed for A-310840 binding to Mn(II)-loaded PfMetAP-II (K d = 666 μM) and EcMetAP-I (K d = 714 μM).
On the other hand, the best fits obtained for the binding of A-311263 to Co(II)-loaded PfMetAP-II and EcMetAP-I
provided an overall n value of 1 and K d values of 0.45 and 2.4 μM, respectively. These values indicate
approximately 58-fold and approximately 21-fold tighter binding than is observed for Mn(II)-loaded PfMetAP-II
and EcMetAP-I, respectively (Table 1).
The heat of reaction, ∆H, measured during an ITC experiment was converted into other thermodynamic
parameters using the Gibbs free energy relationship:

Δ𝐺𝐺 0 = −RTln𝐾𝐾a = Δ𝐻𝐻0 − 𝑇𝑇Δ𝑆𝑆 0 (2)

The thermodynamic parameters for the binding of A-310840 and A-311263 to Co(II)- and Mn(II)-loaded
PfMetAP-II and EcMetAP-I are listed in Table 1. Binding of these inhibitors to both type-I and type-II MetAPs was
found to be spontaneous on the basis of the observed negative Gibbs free energy (∆G). In general, the ∆G values
for the binding of both inhibitors to PfMetAP-II are slightly more negative than the ∆G values obtained for
EcMetAP-I. The energy change associated with Co(II)-loaded EcMetAP-I with A-311263 is weakly endothermic,
with a ΔH value of 1.57 kJ mol−1, while in other cases ΔH was found to be weakly exothermic, with values ranging
between −0.3 and −63 kJ mol−1. It is noteworthy that the entropic factor (T∆S) for the binding of each inhibitor to
PfMetAP-II and EcMetAP-I varies depending on the enzyme and metal ions present. For example, the T∆S values

for the binding of A-310840 to Mn(II)-loaded EcMetAP-I and the binding of A-311263 to Mn(II)-loaded PfMetAPII are negative, whereas in all other cases the observed T∆S values are positive (Table 1).

Electronic absorption spectroscopy

The electronic absorption spectra of Co(II)-loaded PfMetAP-II and EcMetAP-I were recorded in the absence and
presence of A-310840 and A-311263 (Figs. 2, 3) and the absorption due to apoenzyme was subtracted in each
case. The absorption spectra of the uncomplexed wild-type Co(II)-loaded PfMetAP-II and EcMetAP-I enzymes
were identical to those previously reported [23, 28]. Upon the addition of 1 equiv of A-310840 to both Co(II)loaded PfMetAP-II and Co(II)-loaded EcMetAP-I, the molar absorptivities increased by
approximately140 M−1 cm−1. The observed increase in absorbance at approximately 550 nm is similar in
magnitude to that observed at 400 nm, raising the possibility that this increase may be to do to an underlying
charge-transfer or π → π* transition with λ < 400 nm, rather than a change in absorptivity of the d–d bands from
Co(II). Upon closer inspection, the λ max values of the absorption maxima show small blueshifts compared with
those of the wild-type enzymes, indicating that A-310840 directly interacts with the Co(II) active sites of both
EcMetAP-I and PfMetAP-II. Interestingly, the addition of 1 equiv of A-311263 to both Co(II)-loaded PfMetAP-II
and Co(II)-loaded EcMetAP-I also perturbs the visible absorption spectra of Co(II)-loaded EcMetAP-I and
PfMetAP-II, but in a way markedly different from that of A-310840. The maximum molar absorptivity decreases
upon the addition of A-311263 to Co(II)-loaded PfMetAP-II by approximately 50 M−1 cm−1, but the observed λ max
value remains unaffected. The maximum molar absorptivity does not change upon the addition of A-311263 to
Co(II)-loaded EcMetAP-I (approximately 90 M−1 cm−1); however, the λ max value shifts from 580 to 560 nm.

Fig. 2. UV–vis spectrum of wild-type [CoCo(PfMetAP-II)] (dashed line), A-310840 bound to [CoCo(PfMetAP-II)]
(solid line), and A-311263 bound to [CoCo(PfMetAP-II)] (dotted line) in 25 mM N-(2-hydroxyethyl)piperazine-N′ethanesulfonic acid (HEPES) buffer, pH 7.5, and 150 mM KCl. The absorption due to apoenzyme was subtracted
in each case. PfMetAP-II is type-II methionine aminopeptidase (MetAP) from Pyrococcus furiosus

Fig. 3 . UV–vis spectrum of wild-type [CoCo(EcMetAP-I)] (dashed line), A-310840 bound to [CoCo(EcMetAP-I)]
(solid line), and A-311263 bound to [CoCo(EcMetAP-I)] (dotted line) in 25 mM HEPES buffer, pH 7.5, and 150 mM
KCl. The absorption due to apoenzyme was subtracted in each case. EcMetAP-I is type-II MetAP from Escherichia
coli

EPR spectra of A-310840 and A-311263 bound to Co(II)- and Mn(II)-loaded PfMetAP-II
and EcMetAP-I

EPR spectra for both Co(II)-loaded PfMetAP-II and Co(II)-loaded EcMetAP-I have been reported previously [23].
These spectra contain broad features and exhibit no resolvable 59Co hyperfine splitting, presumably owing to
extensive strains in g and/or zero-field-splitting parameters. The spectra observed for Co(II)-loaded PfMetAP-II
and EcMetAP-I upon the addition of A-310840 or A-311263 are shown in Fig. 4 along with computer simulations.
Spin Hamiltonian parameters derived from these simulations are provided in Table 2. In each case, the EPR
spectra of the inhibited forms of Co(II)-loaded PfMetAP-II and EcMetAP-I are very similar to the spectrum from
the corresponding unligated enzyme. The observed signals are dominated by an essentially axial component
with E/D ~ 0.09. For Co(II)-loaded EcMetAP-I + A-310840 (Fig. 4, spectrum B) and Co(II)-loaded PfMetAP-II + A311263 (Fig. 4, spectrum C), a low-field eight-line hyperfine pattern was resolved, indicating the presence of a
second, minor species with markedly lower g eff strain. This signal may also be present in the spectrum of Co(II)loaded PfMetAP-II + A-310840 (Fig. 4, spectrum D), but at very low concentrations, and was not observed for
Co(II)-loaded EcMetAP-I + A-311263 (Fig. 4, spectrum A). In the EPR spectrum of Co(II)-loaded EcMetAP-I bound
by A-310840 (Fig. 4, spectrum B), another feature associated with this second, minor species is observed at an
inflection around 1,900 G. On the basis of this feature, g x,y and hence E/D could be reasonably estimated by
simulation, resulting in an M S = ±½ species with E/D = 0.22. These parameters are typical for five-coordinate
Co(II) centers bound within a rigid coordination sphere [31, 32, 33]. For Co(II)-loaded PfMetAP-II + A-311263
(Fig. 4, spectrum C), only the hyperfine pattern could be distinguished, at lower field than that observed for
Co(II)-loaded EcMetAP-I + A-310840. The actual values of g x,y and E/D for this minor species are dependent on
the identity of the ground-state doublet and therefore cannot be determined from these data.

Fig. 4. EPR spectra of MetAP species containing Co(II). In A–D, the upper spectrum is the experimental spectrum
and the lower spectrum is a computer simulation: [CoCo(EcMetAP-I)] + A-311263 (A); [CoCo(EcMetAP-I)] + A310840 (B); [CoCo(PfMetAP-II)] + A-311263 (C); [CoCo(PfMetAP-II)] + A-310840 (D). Trace E is of naked
[CoCo(PfMetAP-II)]]. Experimental spectra were recorded at 7 K, 0.2 mW (A–C); 9 K, 0.2 mW (D), and 5 K,
0.2 mW (E). Spin Hamiltonian parameters for the simulations are given in Table 2
Table 2. Spin Hamiltonian parameters for the dominant axial and minor rhombic species obtained from the
computer simulation of EPR spectra of Co(II)-loaded EcMetAP-I and PfMetAP-II in the presence of either A310840 or A-311263

Wild-type enzymes
A-310840 binding to wild-type
enzymes
[CoCo(PfMetAP-II)]
[CoCo(EcMetAP-I)]
A-311263 binding to wild-type
enzymes

Axial
g(x,
y)
2.21
2.316

g(z)

E/D

Rhombic
g(x, y) [A(y)
(10−3 cm−1)]

2.09 0.09 ND
2.650 0.095 2.52 [8.6]

g(z)

E/D

ND ND
2.56 0.22

[CoCo(PfMetAP-II)]
[CoCo(EcMetAP-I)]

ND not determined

2.21
2.316

2.09 0.09 2.5–2.9 [10.6]
2.650 0.095 ND

ND
ND

ND
ND

In addition to the S = 3/2 signals observed for each of the Co(II)-loaded MetAP-inhibited complexes, weak signals
were observed between g eff = 10 and 12 in parallel mode (not shown) for Co(II)-loaded PfMetAP-II and
EcMetAP-I bound by A-311263 and Co(II)-loaded EcMetAP-I + A-310840. These data are consistent with S′ = 2
and/or S′ = 3 transitions from an S = 0, 1, 2, 3 spin ladder due to spin coupling between two S = 3/2 Co(II) ions.
While quantification of broad, weak integer spin signals of indeterminate S′ origin and with absorption into zero
field is unreliable, integration of the S = 3/2 components based on simulation of the observed spectra suggested
that approximately 85 ± 10% of the Co(II) ions are accountable for by the observed S = 3/2 species. The observed
integer-spin signals are particularly pronounced for Co(II)-loaded PfMetAP-II + A-311263, and the same integerspin transitions are likely due to the EPR absorption at very low field (0–500 G) observed in normal-mode EPR
(Fig. 4, spectrum C; a small amount of such a signal was included in the simulation but parameters are not given
as no attempt was made to fully characterize or quantify this signal). It is unlikely that these signals are
dependent upon the inhibitor as similar low-field signals are observed for uncomplexed Co(II)-loaded PfMetAP-II
(Fig. 4, spectrum E) and EcMetAP-I enzymes at high pH. Indeed, the lack of such signals from Co(II)-loaded
PfMetAP-II + A-310840 may be of more significance.
The EPR spectra of Mn(II)-loaded EcMetAP-I and PfMetAP-II complexed with either A-310840 or A-311263 are
presented in Fig. 5. When Mn(II)-loaded EcMetAP-I and PfMetAP-II were incubated with A-310840, both
enzymes displayed signals superficially similar to those of the corresponding wild-type enzymes. Characteristic
central six-line patterns with approximately 90 G splitting and Curie law temperature dependence are observed,
as well as additional features that demonstrate Boltzmann temperature dependence and an approximately 45 G
splitting [25, 26]. The central six-line patterns observed for Mn(II)-loaded EcMetAP-I and PfMetAP-II bound by A310840 are somewhat lower in intensity compared to those of wild-type forms of the enzymes, but the
individual lines are better resolved. However, the resonance positions of the transitions in the 3,000–3,800-G
region of the spectra are indistinguishable (Fig. 5, spectra F, H). Both sets of spectra provide other features with
Boltzmann temperature dependence that exhibit approximately 45 G splitting, characteristic of dinuclear Mn(II)
centers (Fig. 5, spectra I, K, L, N).

Fig. 5. EPR spectra from MetAP containing Mn(II). Traces A–E are 6,000-G (600-mT) experimental scans. Traces F,
G, and H and I, J, and K are expanded views of selected regions of A, B, and C, respectively. Traces L, M, and N
are derivatives of traces I, J, and K, respectively. The traces correspond to [MnMn(EcMetAP-I)] + A-310840 (A, F,
I, L), [MnMn(EcMetAP-I)] + A-311263 (B, G, J, M), [MnMn(Pf(MetAP-II)] + A-310480 (C, H, K, N), and
[MnMn(Pf(MetAP-II)] + A-311263 (D). Trace E is a computer simulation of trace D assuming S = 5/2, g = 2.0, A
−3
−1
−3
−1
−3
−1
I = 5/2 = 8.8 × 10 cm , D = 86 × 10 cm , σD = 7 × 10 cm , E/D = 0, and σE/D = 0.14. Experimental spectra
were recorded at 30 K, 0.2 mW (A–C, F–H, I–K) or at 40 K, 0.2 mW (D)
In contrast, the addition of A-311263 to Mn(II)-loaded EcMetAP-I and PfMetAP-II provided EPR spectra that are
distinctly different from those of wild-type Mn(II)-loaded enzymes. The spectrum of Mn(II)-loaded EcMetAPI + A-311263 contained a central six-line pattern (Fig. 5, spectrum G) indistinguishable from the patterns of the
A-310840 complexes and wild-type enzymes. However, this signal did not exhibit the Boltzmann-temperaturedependent “wings” at 2,200–2,600 G with approximately 45 G splittings that are characteristic of Mn(II)–Mn(II)
spin–spin coupling (Fig. 5, spectra J, L). More dramatic differences were seen in the spectrum of Mn(II)-loaded
PfMetAP-II + A-311263 (Fig. 5, spectrum D). A very complex spectrum was observed that had intense features
across the field range 0–6,000 G. The form of this spectrum was essentially invariant from 5 to 40 K and
exhibited Curie law temperature dependence, suggesting that the features are due to isolated S = 5/2 Mn(II)
ions. Indeed, this signal could be well simulated assuming a single Mn(II) species with spin Hamiltonian
parameters S = 5/2, g = 2.0, A I = 5/2 = 8.8 × 10−3 cm−1, D = 86 × 10−3 cm−1, σD = 7 × 10−3 cm−1, E/D = 0, and
σE/D = 0.14 (Fig. 5, spectrum E).

Discussion
Type-II MetAPs have been identified as the molecular target for antiangiogenesis agents such as fumagillin and
its derivatives [3, 34], whereas type-I MetAPs have been suggested to be potential antibacterial and/or
antifungal targets [35, 36]. Therefore, developing a detailed understanding of how potential small molecule drug

candidates interact with the active sites of MetAPs will facilitate the rational design of new, potent MetAP
inhibitors with improved in vivo stability and cytotoxicity [37]. As one might expect, most of the information
regarding the binding of MetAP inhibitors has come from the inspection of X-ray crystal structures [22, 38, 39].
Although such crystallographic information is extremely valuable, it represents a static view that may not be
representative of a dynamic enzyme. Thus, detailed solution characterization of MetAP drug candidates is
critically important in the design and development of new drugs. Herein we have investigated the binding
affinities and the spectroscopic properties of two inhibitors of PfMetAP-II and EcMetAP-I, namely, a triazolecontaining inhibitor 3-((2-naphthylmethyl)sulfanyl)-4H-1,2,4-triazole (A-310840) and a bestatin-like inhibitor
((2RS,3R)-3-amino-2-hydroxy-5-ethylthio)pentanoyl-((S)-(−)-(1-naphthyl)ethyl)amide (A-311263) [25].
Examination of the inhibition patterns of both Co(II)- and Mn(II)-loaded EcMetAP-I and PfMetAP-II in the
presence of A-310840 and A-311263 revealed that they are both moderately strong competitive inhibitors. A310840 preferentially inhibits Co(II)-loaded EcMetAP-I and PfMetAP-II enzymes over the Mn(II)-loaded enzymes,
whereas A-311263 shows little or no metal ion selectivity for either type-I or type-II enzymes. The observed K i
values follow the same trend as the IC50 values obtained for EcMetAP-I, PfMetAP-II, and HsMetAP-II except that
the IC50 values are substantially weaker for the two bacterial enzymes compared with the human type-II enzyme
[25]. For competitive inhibitors, the observed K i value is equal to the dissociation constant (K d); therefore, ITC
not only provides the opportunity to compare experimentally derived K d values with K i values, but also to
obtain thermodynamic parameters for inhibitor binding to both the PfMetAP-II and EcMetAP-I enzymes in a
single experiment. The K d values derived from ITC are in reasonable agreement with the kinetically derived K i
values (Table 1). The observed enthalpies (∆H) for the binding of A-310840 and A-311263 to Mn(II)-loaded
PfMetAP-II and EcMetAP-I are negative. However, both A-310840 and A-311263 exhibited positive ∆H values for
binding to Co(II)-loaded EcMetAP-I but negative ∆H values for binding to Co(II)-loaded PfMetAP-II. These data
exemplify the active-site differences between type-I and type-II MetAPs and indicate that Mn(II)-loaded MetAPs
more favorably bind these inhibitors, and possibly substrates. Interesting, the entropic factor (T∆S) follows an
opposite trend, with inhibitor binding to the Co(II)-loaded enzymes being more entropically favored than
inhibitor binding to Mn(II)-loaded MetAPs. Combination of the observed ∆H and T∆S values for A-310840 and A311263 binding to both the Co(II)-loaded and the Mn(II)-loaded PfMetAP-II and EcMetAP-I enzymes are all
negative, indicating that inhibitor binding is spontaneous. However, the observed ∆G values favor inhibitor
binding to the Co(II)-loaded PfMetAP-II and EcMetAP-I enzymes over the Mn(II)-loaded forms by nearly 30%.
To gain some structural insight into how A-310840 and A-311263 bind to both type-I and type-II MetAPs in the
presence of either Mn(II) or Co(II), electronic absorption and EPR spectra were recorded in the presence of each
inhibitor. The observed changes in electronic absorption spectra of the Co(II)-loaded forms of PfMetAP-II and
EcMetAP-I upon A-310840 and A-311263 binding indicate that each ligand interacts with the active-site Co(II)
ions. Moreover, the observed molar absorptivities upon A-310840 binding to Co(II)-loaded EcMetAP-I and
PfMetAP-II suggest that the active-site Co(II) ions are five-coordinate, while A-311263 binding provides a Co(II)
environment that is five- or six-coordinate [40]. Similarly, the observed EPR spectra of the Co(II)-loaded
EcMetAP-I and PfMetAP-II enzymes in the presence of A-311263 are due to transitions in the M S = ±½ Kramers
doublets and arise from either five- or six-coordinate Co(II) ions The broad, featureless EPR signals from the
dominant axial components of the spectra indicate significant structural microheterogeneity in each case; thus,
there is a great deal of flexibility in the ligand environment, perhaps related to coordination by water. For Co(II)loaded EcMetAP-I and PfMetAP-II enzymes in the presence of A-310840 a minor species, in some cases with
well-resolved hyperfine splitting and significant rhombic distortion of the axial zero-field splitting, is observed,
suggesting an alternative geometry with a rigid coordination environment and likely five-coordinate geometry
[41, 42]. Similar species observed in the EPR spectra of Co(II)-substituted forms of the aminopeptidase from
Aeromonas proteolytica have been shown to be pH-dependent [41, 42].
For a small percentage (less than 15%) of Co(II) ions bound to either the EcMetAP-I or PfMetAP-II enzymes in the
presence of A-311263 and the Co(II)-loaded form of EcMetAP-I bound by A-310840, a weak integer spin signal in

the parallel mode is observed. However, for Co(II)-loaded PfMetAP-II bound by A-310840, no integer spin signal
is observed. EPR studies on Co(II)-loaded EcMetAP-I revealed that at pH 7.5 there is no significant spin coupling
between the two Co(II) ions, though a small proportion (approximately 5%) of the sample exhibited detectable
spin–spin interactions at pH values above 9.6 [23]. Therefore, the integer spin signals observed for the EcMetAPI-inhibited enzymes are likely due to inhibitor binding since no spin–spin interactions are observed in the
absence of inhibitor. Conversely, the uncomplexed form of Co(II)-loaded PfMetAP-II exhibits detectable
(approximately 15%) spin–spin interactions at pH 7.5. Thus, the observed integer spin signal for Co(II)-loaded
PfMetAP-II bound by A-311263 is identical to that for the uncomplexed enzyme, suggesting that the binding of
A-311263 does not provide a single atom bridge between the two Co(II) ions bound in the active site. However,
the lack of an observable integer spin signal when A-310840 is complexed with Co(II)-loaded PfMetAP-II suggests
that A-310840 may modulate antiferromagnetic coupling via a diazine bridge. Such a coupling interaction is
consistent with the limited number of diazine-bridged dinuclear Co(II) model complexes [43, 44, 45]. The lack of
intense parallel-mode signals is likely due to the weak K d values observed for the second Co(II) binding event
(0.35 and 2.5 mM for PfMetAP-II and EcMetAP-I, respectively), which provides enzyme samples containing a
mixture of both mononuclear and dinuclear Co(II) centers with the majority of sites in the mononuclear state
[23, 28]. For dinuclear Co(II) species, it appears that the binding of either A-311263 or A-310840 modulates the
exchange interaction between the Co(II) ions by altering the precise nature of the electronic wavefunction
overlap network (i.e., the bonding network) between these ions.
Both PfMetAP-II and EcMetAP-I exhibit distinct binding constants for two Mn(II) ions, and the higher of these, K
d2, dictates that distinct MetAP species containing either one or two Mn(II) ions will be present in samples
prepared even at millimolar concentrations [22, 46, 47]. The dinuclear forms have been shown to contain two
Mn(II) ions in close proximity and, for both PfMetAP-II and EcMetAP-I, features in the EPR spectra have been
identified that clearly show spin–spin interaction between the two Mn(II) ions [43, 44, 45, 46]. As expected, EPR
spectra obtained for the Mn(II)-loaded forms of both PfMetAP-II and EcMetAP-I in the presence of either A311263 or A-310840 indicate the presence of magnetically isolated S = 5/2 Mn(II) ions coordinated by oxygenand nitrogen-containing ligands [46]. The S = 5/2 components of the spectra with A-310840 were
indistinguishable from those of the corresponding resting enzymes. The EPR spectra of PfMetAP-II and EcMetAPI incubated with A-310840 exhibited features that are characteristic of spin–spin coupling between the Mn(II)
ions; again, these features were very similar to those exhibited by the corresponding resting enzymes. The lack
of significant perturbation of the electronic structure of the monomanganese and dimanganese species of these
enzymes by A-310840 is likely related to the poor efficacy of this inhibitor for the manganese forms of PfMetAPII and EcMetAP-I.
Significant differences in the electronic structures of the Mn(II) complements of PfMetAP-II and EcMetAP-I were
elicited by incubation with A-311263 in contrast to incubation with A-310840. In the case of Mn(II)-loaded
EcMetAP-I + A-311263, no signals or temperature-dependent features corresponding to spin-coupled Mn(II)–
Mn(II) were observed between 5 and 50 K. This observation suggested the loss of any spin–spin interaction. The
loss of the S′ = 1, 2,…, 5 signals would be expected to result in an increase in the S = 5/2 signal intensity due to
the newly separated Mn(II) ions; the loss of the dipolar component of the coupling would, of course, entail
physical separation of the two Mn(II) ions. Intriguingly, no significant enhancement of the central six-line pattern
signal intensity was observed. Therefore, it is unclear whether no inter-Mn(II) interaction exists or whether the
interaction is present but unobservable. An unusually high spin-coupling constant (|J| ≫ 35 cm−1) would prevent
the population of S′ > 0 levels owing to zero-field splitting within the non-Kramers doublets of populated S′ > 0
states (Δ > 0.3 cm−1), which results from broadening by large increases in the values and/or distributions of the
individual Mn(II) zero-field-splitting parameters. Alternatively, a relaxation-dependent phenomenon may be in
play. Regardless, the inter-Mn(II) interaction in Mn(II)-loaded EcMetAP-I is significantly perturbed, either
abolished or greatly enhanced, by A-311286.

The EPR spectrum obtained for Mn(II)-loaded PfMetAP-II + A-311286 looked completely different from any
other EPR signal observed for a MetAP species but was very similar to the EPR signal observed for the argEencoded N-acetyl-l-ornithine deacetylase from E. coli [47]. Despite the complexity of this signal, it was simulated
as a single S = 5/2 Mn(II) environment, consistent with its temperature dependence. The lack of an intense
central six-line pattern is due to a distribution in E/D; although the system is nominally axially symmetric with a
mean E/D = 0 assumed for the sample, the distribution results in a significant proportion of the molecules in the
sample exhibiting E/D ≠ 0. Thus, it appears that a rhombic distortion is introduced into the electronic
symmetries of the Mn(II) ions bound to PfMetAP-II upon complexation with A-311286. Similar to Mn(II)-loaded
EcMetAP-I, no evidence is observed for inter-Mn(II) spin coupling in the EPR spectrum obtained for Mn(II)loaded PfMetAP-II + A-311286, further supporting the contention that the active site is significantly perturbed by
A-311286.
The X-ray crystal structure of A-311263 bound to HsMetAP-II revealed the presence of a μ-alkoxide bridge [48].
In addition, the X-ray crystal structure of a related purported substrate-analog inhibitor (3R)-amino-(2S)
hydroxyheptanoyl-l-Ala-l-Leu-l-Val-l-Phe-OMe (SK-V-126) bound to EcMetAP-I has been reported [18]. In this
structure, the N-terminal amine coordinated Co2, the keto oxygen (analogous to the carbonyl carbon in a
terminal peptide bond) is ligated to Co1, and the (2S)-hydroxyl group displaces the bridging water/hydroxide ion
[1, 18]. Taken together with the EPR data, which primarily contain data for mononuclear enzyme species, this
suggests the alkoxide moiety displaces the water (hydroxide) oxygen atom and is terminal on M1, while the Nterminal amine nitrogen of the inhibitor is bound by the carboxylate groups making out the purported second
metal binding [22]. Inspection of the X-ray crystal structure of the dicobalt(II) form of type-I MetAP from S.
aureus complexed with a 1,2,4-triazole-based inhibitor and the crystal structure of a 1,2,3-triazole-based
inhibitor bound to the dicobalt(II) form of HsMetAP-II reveals that a common feature for the triazole derivative
in enzyme recognition is the interaction of the nitrogen atoms in positions 1 and 2 with the dicobalt(II) center
such that their N–N bond is nearly collinear with the metal–metal vector in the dinuclear site [49, 50, 51].
Combination of EPR and crystallographic data suggests that when two metal ions are bound to MetAPs, A310840 binds via a diazine bridge (Fig. 6). On the other hand, when only one Co(II) ion is bound in a MetAP
active site, binding of A-310840 clearly results in a more rigid five-coordinate environment. Conversely, the
addition of A-310840 does not markedly perturb the EPR spectra of either Mn(II)-loaded PfMetAP-II or Mn(II)loaded EcMetAP-I. These data indicate nonbinding or a very weak binding interaction of the triazole ligand with
the Mn(II) ions bound in the MetAP active sites. Therefore, the specificity of A-310840 for Co(II) over Mn(II) is
likely due to Co(II)’s preference for softer donor ligands (nitrogen) over harder donor ligands (oxygen) [52, 53].
However, this explanation does not tell the entire story. Since MetAPs are likely a mixture of mononuclear and
dinuclear enzymes under physiological conditions [54, 55] and the putative partially empty, second metal
binding site is carboxylate-rich, the lone pair of electrons on the N2 atom of the triazole ligand will be repelled
by the negative charge associated with the carboxylate groups in this site. Alternatively, the N-terminal amine
moiety of A-311263 will form a zwitterionic interaction with this carboylate site, resulting in an additional
binding interaction over the A-310840 molecule (Fig. 7). This hypothesis is consistent with the observed
thermodynamic parameters for both A-310840 and A-311263 binding to Co(II)- and Mn(II)-loaded PfMetAP-II or
EcMetAP-I, particularly in the decrease in ΔG observed for A-310840 binding to Mn(II)-loaded MetAPs compared
with Co(II)-loaded enzymes.

Fig. 6. Proposed scheme for binding of A-310840 to the active sites of both Co(II)- and Mn(II)-loaded EcMetAP-I
(residue numbering) and PfMetAP-II

Fig. 7. Proposed scheme for binding of inhibitor A-311263 to the active site of both Co(II)- and Mn(II)-loaded
EcMetAP-I (residue numbering) and PfMetAP-II
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